
usd dec pm et
summari compani distributor pharmaceut medical-surg suppli
relat product broad rang health care custom
nm price-to-earnings oper ep
drug medic suppli distributor like see
attract long-term volum growth due develop
popul age increas health care util
expand global middl class gain access
advanc medicin barrier entri industri
also high three firm control
 drug distribut posit balanc
limit price power due consolid larg
custom opioid litig risk vertic
integr medic devic manufactur also bring
oper litig risk pure
distributor view
feb ep estim base cfra oper earn
histor earn report compani report
stk
dividend paid sinc compani report
past perform indic futur perform
reli upon
forecast reliabl indic futur perform
past perform indic futur perform reli upon
analysi prepar equiti analyst
pm stock trade
year-to-d sale grew yoy led
revenu yoy
benefit volum growth
convent drug distribut strong
demand specialti pharmaci medic
yoy see low demand growth
howev payer work shift
care hospit focus
lower cost facil urgent care
despit year revenu growth ytd
adjust pre-tax incom yoy
margin continu downward
trend began think
driven unfavor contract renew term
larg custom due limit
price power servic
undifferenti peer custom
gain bargain power due health care
provid insur pbm continu
integr view
notabl bright spot year
distribut sg cost
yoy ytd period despit
signific revenu growth think
reflect improv distribut effici
import off-set less profit
term distribut contract
neutral share see limit
steadili grow babi boomer drive
higher health care util expect
mostli off-set lower margin
leverag also poor outlook
hospit suppli segment see care
shift lower cost outpati facil
away hospit think
consolid health insur provid
pharmaci benefit manag on-going
trend saw combin aetna
express script
walgreen acquir much insur
also continu acquir region
provid trend pressur
oper margin larger
custom abl negoti lower
target price fy jun ep
estim histor forward price-to-earnings
averag see margin pressur continu
downsid risk includ sever
gener price deflat contract renew
less favor term highli uncertain
redistribut reproduct prohibit without written permiss copyright cfra document intend provid person invest advic take account specif invest
object financi situat particular need specif person may receiv report investor seek independ financi advic regard suitabl and/or appropri make
invest implement invest strategi discuss document understand statement regard futur prospect may realiz investor note incom
invest may fluctuat valu invest may rise fall accordingli investor may receiv back less origin invest investor seek advic concern impact
invest may person tax posit tax advisor pleas note public date document may contain specif inform longer current use make
invest decis unless otherwis indic intent updat document
corpor overview inc third largest health care distribut compani
 connect manufactur pharmaceut medic suppli broad rang
downstream custom includ pharmaci hospit outpati surgeri center clinic
laboratori oper two segment revenu oper profit
fy jun medic
pharmaceut distribut tradit brand gener drug well specialti drug
oncolog infus medic medic manufactur distribut broad rang product
medic glove endovascular stent segment util nation network distribut
center focus medic oper canada europ
asia oper margin gener higher medic fy saw medic oper margin
versu
largest custom optumrx pharmaci account roughli
revenu respect five largest custom account revenu distribut
agreement extend june optumrx extend june
market profil increas access health insur especi global middl class expand
well age popul develop nation posit demand driver health care distribut
long term view drug price inflat deflat howev one critic
factor drug distribut profit short term return wareh logist inventori
data servic larg distribut contract typic pay distributor negoti percentag health care
provid purchas order amount drug manufactur actual drug price negoti
drug manufactur downstream provid rise drug price therefor lead larger whole dollar
servic fee distributor inflat also help distributor tradit resal arrang
purchas bulk inventori manufactur resel downstream custom see profit
rise lower-cost exist inventori sold rise price
big three pharmaceut distributor
pursu consolid strategi recent year lead increas combin market
share addit gener drug sourc joint ventur larg retail pharmaci
becom standard began collabor jv improv bargain power
gener manufactur set similar jv walgreen
increas bargain power manufactur like factor gener price deflat trend
last sever year contribut view pharmaceut sale growth slow
last year slower growth tradit drug busi led distributor seek higher growth
margin relat busi specialti pharmaceut medic suppli
corpor strategi differenti big three pharma distributor due
greater exposur medic suppli manufactur distribut medic segment
focus grow busi well specialti drug busi captur higher growth
margin creat one-stop-shop health care provid purchas medic
suppli medicin one vendor
recent activ significantli expand medic segment includ octob
acquisit cordi global manufactur distributor cardiolog devic june
acquisit patient recoveri busi manufactur distribut
medic product categori cordi signific drag earn growth due oper
problem inventori write-down mount litig cost help fuel goodwil
impair medic segment fiscal
competit landscap oper highli competit environ particularli larg
rival segment medic suppli busi acute-car
provid one top two distributor alongsid owen minor barrier entri
industri high due scale capit intens supply-chain infrastructur possess
larg incumb price power extrem limit current environ due custom
consolid polit pressur lower health care cost
price breadth product offer value-ad servic credit term primari competit
factor industri larg multi-year contract consolid amongst downstream custom
major impact distributor earn case lost signific
pharmaci busi merger safeway albertson renew
optumrx contract materi lower margin also medic suppli distribut
agreement kaiser permanent health network incumb
financi trend total revenu increas billion fy billion fy
repres three-year compound annual growth rate compound-annual-growth-rate revenu growth
boost sever acquisit period howev adjust pre-tax incom per share
account ad capit oper cost acquisit fell fy
fy three-year compound-annual-growth-rate neg drop incom driven steep
declin oper margin period leverag moder view fy adjust
oper incom cover net interest expens healthi
redistribut reproduct prohibit without prior written permiss copyright cfra
base cfra proprietari quantit model
stock rank overvalu
bullish sinc septemb technic indic
bullish
figur base fiscal year-end price
growth rate averag
lt debt capit
return equiti
balanc sheet data million usd
oper
long term debt capit
net incom revenu
return asset
return equiti
 global market intellig data may preliminari restat result discontinu operations/speci item per share data adjust stock dividend ep dilut
redistribut reproduct prohibit without prior written permiss copyright cfra
fundament outlook health care
distributor sub-industri next year
neutral driven mix posit
neg factor posit side see
distribut revenu bolster growth
prescript volum slowdown brand
drug patent expir neg side
expect profit margin see continu
pressur consolid drug suppli
chain focu mainli drug
distribut busi gener
sub-industri revenu
prescript drug demand continu
increas turn drive
greater volum handl distributor
driven view age
babi boomer prime util year
gain health-insur popul
accord latest censu data
age cohort grow five time fast
total popul expect age
drive long-term growth prescript drug
demand senior tend health care
need younger cohort
addit recent censu data
indic health-insur
popul continu grow million
individu ad health plan
view peopl health insur
like prescript written fill
uninsur due manag
cost doctor visit drug insur
expect growth health-insur
popul continu year ahead
strong labor market especi
full-tim employ pull peopl onto
employ growth averag first
eight month line
job growth experienc
moreov full-tim job growth
outpac part-tim job growth bp
along rise prescript volum
distributor tend benefit higher
price brand drug gener
expect brand support favor
period low patent expir year
ahead data evaluatepharma indic
annual global drug sale risk expir
patent averag total
clear way substanti
amount lower-pr gener enter
market expir forecast drop
howev
posit brand drive
higher revenu distributor
typic collect percentag drug price
exchang manufactur
pharmaci exchang wareh
ship data track servic yet
longer term think brand drug price
face risk new regul politician
increasingli focus control voter
drug cost see outlook
immedi concern distributor
view grow scale
player drug suppli chain
consolid drug maker upstream
well pbm manag care firm
provid downstream on-going
negoti power supplier
custom distributor limit
abil improv oper margin
declin
year-to-d septemb
distributor index rose
base index
five-year market price perform dec
note sector sub-industri inform base
past perform indic futur perform
reli upon
yield equiti
ltd
peer group compani stock select issu base market capit
note peer select base global industri classif standard market capit peer group list includ compani similar characterist may includ compani within
industri and/or engag line busi
redistribut reproduct prohibit without prior written permiss copyright cfra
et cfra maintain hold opinion share inc
keep target fy jun ep
estim -- discount histor forward price-to-earnings averag expect
continu margin contract keep fy ep estim lower
fy dec-q ep vs ahead
consensu driven higher-than-expect revenu dec-q sale yoy
mark three straight quarter impress sale gain
driven higher volum lower sale price rise raw materi cost
continu pressur margin gross margin bp yoy effici
initi appear gain traction though sg expens
yoy overal adjust pre-tax incom flat yoy per share basi rose
reduc share count yoy aggress repurchas
share appear cheap trail earn continu concern
lack price power declin profit margin /colin scarola
et cfra keep hold opinion share cardin inc
rais target ep
estim discount histor averag forward price-to-earnings
signific headwind earn keep fy jun ep
estim lower sept-q ep vs
ahead consensu gener strongest quarter
revenu growth two year yoy estim adjust pre-tax incom
versu prior year period gross margin materi worsen
sg appear rise faster sale gener deflat
pharma segment revenue rise raw materi cost medic
segment drove drop gross margin quarter
year appear cheap trail earn continu
concern path stabil oper earn expect
sever gener deflat continu along rise cost
analyst research note compani news
pm et cfra maintain hold opinion share inc
lift target fy jun ep
estim -- histor forward price-to-earnings averag due margin
contract maintain fy ep estim drop fy
sep-q ep vs beat consensu medic oper
profit total grew impress yoy long-term effici
initi gain traction pharmaceut oper profit fell
yoy howev neg impact renew largest custom
less profit term expect pharma earn declin even faster
yoy fy contrast sharpli peer whose oper
earn see grow next year attribut diverg
lower market share rapidli grow specialti drug
immuno-oncolog encourag improv medic think
below-p valuat warrant given primari pharma segment
declin peer grow /colin scarola
et cfra see investor sentiment improv defend
nation opioid case key bellweth trial opioid
epidem schedul begin monday intent presid judg
bring side comprehens settlement resolv relat
case nationwid trial approach see flurri report
settlement negoti includ news week big drug
distributor propos cap total liabil pay
year produc teva offer settlement worth
respect earli know coalit
state attorney lead negoti behalf plaintiff stand
offer see defend willing settl posit news opioid
litig uncertainti gener cost defend market valu via
neg sentiment like cost settl view move
toward settlement even costli one defend see share rise
uncertainti allevi /colin scarola
et cfra maintain hold opinion share inc
lower target fy jun ep
estim histor forward price-to-earnings averag due margin contract
lower fy ep estim initi fy
jun-q ep vs beat consensu jun-q revenu grew
yoy led yoy growth pharmaceut revenu pharmaceut
also grew oper profit total yoy
encourag sign investor end straight quarter
oper profit declin stretch back gener price
deflat continu headwind
off-set strong demand specialti drug medic oper profit
fell yoy jun-q howev driven rise cost relat
cardin brand product strategi think averag valuat
warrant demonstr invest medic segment
deliv adequ return capit /colin scarola
et cfra maintain hold opinion share inc
lower target fy jun ep
estim histor forward price-to-earnings averag due margin contract
rais fy ep estim maintain fy mar-q
ep vs beat consensu materi drop tax
rate mask yoy drop pre-tax incom mar-q revenu grew yoy
led yoy growth revenu off-set
yoy drop medic think organ sale growth drug
distribut fastest peer strong top line
translat higher oper earn drug distribut margin continu
rapidli contract peer held
margin roughli flat yoy mar-q think poor margin trend
partial due rel low mix profit specialti drug
distribut busi think margin need stabil share
note research note reflect cfra publish opinion analysi stock time note publish note reflect view equiti analyst date time
indic note may reflect cfra current view compani
redistribut reproduct prohibit without prior written permiss copyright cfra
fiscal year analyst estim earn
usd quarter fiscal year
announc earn per share usd
repres total revenu estim
fiscal year analyst estim earn
per share grow usd
total
estimate
forecast reliabl indic futur perform
note compani earn outlook play major part invest decis global market intellig organ earn estim wall street analyst
provid consensu earn next two year well earn estim chang time note inform provid relat consensu
estim intend predict actual result taken reliabl indic futur perform
note tabl graph chart report cite refer sourc sourc global market intellig
redistribut reproduct prohibit without prior written permiss copyright cfra
sinc januari cfra equiti fund research servic
predecessor capit iq equiti research rank univers
common stock adr american depositari receipt adss american
depositari share base given equiti potenti futur perform
similarli rank asian european equiti sinc june
rank equiti accord individu forecast equiti futur total
return potenti versu expect total return relev benchmark
region index asia europ
base time horizon star design meet need
investor look put invest decis perspect data use
assist determin star rank may result analyst
model well intern proprietari model result dynam data
also known
 growth
stabil earn dividend deem key element establish
global market intellig earn dividend rank common stock
design capsul natur record singl symbol
note howev process also take consider certain
adjust modif deem desir establish rank
final score stock measur score matrix determin
analysi score larg repres sampl stock
rang score array sampl align follow
ladder rank
cfra earn per share ep estim reflect analyst project futur
ep continu oper gener exclud variou item
view special non-recur extraordinari also ep estim reflect
either forecast equiti analyst consensu averag ep estim
independ compil global market intellig data
provid cfra among item typic exclud ep estim
asset sale gain impair restructur merger-rel charg legal
insur settlement process research develop expens gain
loss extinguish debt cumul effect account
chang earn relat oper classifi
compani discontinu inclus item stock option
expens recur type charg may vari depend
factor industri practic analyst judgment extent
type data disclos compani
equiti analyst project market price given secur command
month henc base combin intrins rel privat
cfra equiti research produc distribut account research
analyt llc d/b/a cfra cfra us togeth affili
subsidiari cfra certain research produc distribut cfra
sdn bhd compani formerli known standard poor
malaysia sdn bhd cfra malaysia certain research distribut cfra uk
limit cfra uk cfra uk cfra malaysia wholly-own subsidiari
cfra us
abbrevi use equiti research report
ebit earn interest tax
redistribut reproduct prohibit without prior written permiss copyright cfra
p/nav price net asset valu ratio price-to-earnings-to-growth ratio pv present
 research develop roce return capit employ roe
return equiti
roi return invest
 return invest capit
roa return asset
wacc weight averag capit
dividend american depositori receipt adr american depositori
share adss net tax paid countri origin
reflect equiti analyst view given compani oper risk
risk firm abil continu on-going concern qualit risk
assess rel rank star univers
reflect risk factor relat compani oper oppos risk
volatil measur associ share price etf reflect
capitalization-weight basi averag qualit risk assess
assign hold fund
star rank system definit
total return expect outperform total return relev benchmark
notabl margin come month share rise price
total return expect outperform total return relev benchmark
come month share rise price absolut basi
total return expect close approxim total return relev
benchmark come month share gener rise price
absolut basi
total return expect under-perform total return relev
benchmark come month share price anticip
total return expect under-perform total return relev
benchmark notabl margin come month share fall
price absolut basi
north america relev benchmark europ
asia relev benchmark europ asia
